Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

Authors

  • Roberto Ravasio Health Publishing & Services S.r.l., Milan - Italy
  • Roberto Giacomelli Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L’Aquila, L’Aquila - Italy
  • Stefano Bianchi Unità Operativa Servizio farmaceutico ospedaliero e territoriale Azienda Usl Ferrara - Italy

DOI:

https://doi.org/10.33393/grhta.2020.2187

Keywords:

Anakinra, Still's disease

Abstract

In the article, “Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease”,[1] which appeared in Volume 7, Issue 1 of  Global & Regional Health Technology Assessment, the number of patients undergoing treatment with tocilizumab and anakinra displayed in Table V (column Current Scenario) was inadvertently inverted. Affected data have been corrected in the article now appearing online. The authors apologize for any inconvenience caused to the readers by these changes, which do not affect the final results of the study. 

The final version of this article is available online and includes a reference to this correction.

Downloads

Download data is not yet available.

Downloads

Published

2020-09-30

How to Cite

Ravasio, R., Giacomelli, R., & Bianchi, S. (2020). Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease. Global and Regional Health Technology Assessment, 7(1), 91. https://doi.org/10.33393/grhta.2020.2187

Issue

Vol. 7 No. 1 (2020): January-December 2020

Section

Erratum

Categories

License

Copyright (c) 2020 The authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

 

Received 2020-09-20
Accepted 2020-09-20
Published 2020-09-30

Metrics

Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)

<< < 1 2 3 4 > >>